6C49

ICD-11 MMS 2026-01

Disorders due to use of hallucinogens

Description

Disorders due to use of hallucinogens are characterised by the pattern and consequences of hallucinogen use. Several thousand compounds have hallucinogenic properties, many of which are found in plants (e.g., mescaline) and fungi (e.g., psilocybin) or are chemically synthesized (e.g., lysergic acid diethylamide [LSD]). These compounds have primarily hallucinogenic properties, but some may also be stimulants. Much of the morbidity associated with these compounds arises from the acute effects related to Hallucinogen Intoxication. Hallucinogen Dependence is rare and Hallucinogen Withdrawal is not described. Among the mental disorders related to hallucinogen use, Hallucinogen-Induced Psychotic Disorder is the most frequently seen, although worldwide it is still fairly uncommon.

Exclusions from above levels

  • QE62 – Uncomplicated bereavement
  • QE84 – Acute stress reaction

Child codes

  • 6C49.0 – Episode of harmful use of hallucinogens
  • 6C49.1 – Harmful pattern of use of hallucinogens
  • 6C49.2 – Hallucinogen dependence
  • 6C49.3 – Hallucinogen intoxication
  • 6C49.4 – Hallucinogen-induced delirium
  • 6C49.5 – Hallucinogen-induced psychotic disorder
  • 6C49.6 – Certain specified hallucinogen-induced mental or behavioural disorders
  • 6C49.Y – Other specified disorders due to use of hallucinogens
  • 6C49.Z – Disorders due to use of hallucinogens, unspecified

Sibling codes

  • 6C40 – Disorders due to use of alcohol
  • 6C41 – Disorders due to use of cannabis
  • 6C42 – Disorders due to use of synthetic cannabinoids
  • 6C43 – Disorders due to use of opioids
  • 6C44 – Disorders due to use of sedatives, hypnotics or anxiolytics
  • 6C45 – Disorders due to use of cocaine
  • 6C46 – Disorders due to use of stimulants including amphetamines, methamphetamine or methcathinone
  • 6C47 – Disorders due to use of synthetic cathinones
  • 6C48 – Disorders due to use of caffeine
  • 6C4A – Disorders due to use of nicotine
  • 6C4B – Disorders due to use of volatile inhalants
  • 6C4C – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
  • 6C4D – Disorders due to use of dissociative drugs including ketamine or phencyclidine (PCP)
  • 6C4E – Disorders due to use of other specified psychoactive substances, including medications
  • 6C4F – Disorders due to use of multiple specified psychoactive substances, including medications
  • 6C4G – Disorders due to use of unknown or unspecified psychoactive substances
  • 6C4H – Disorders due to use of non-psychoactive substances
  • 6C4Y – Other specified disorders due to substance use
  • 6C4Z – Disorders due to substance use, unspecified

Foundation entity

Disorders due to use of hallucinogens – http://id.who.int/icd/entity/1967909777

Allowed postcoordination axes

Part of: 06: Mental, behavioural or neurodevelopmental disorders